Prognostic significance of hypopigmentation in malignant melanoma - PubMed (original) (raw)
Comparative Study
. 1987 Aug;123(8):1053-5.
- PMID: 3631983
Comparative Study
Prognostic significance of hypopigmentation in malignant melanoma
J C Bystryn et al. Arch Dermatol. 1987 Aug.
Abstract
It has been suggested that the presence of cutaneous hypopigmentation favorably influences the prognosis of patients with malignant melanoma (MM). To examine this possibility, we have compared the actual with the predicted survival of 46 patients with MM and hypopigmentation who were among 1130 patients with MM entered in a long-term prospective study of MM at the New York University Medical Center. The actual average five-year survival rate of the patients with MM and hypopigmentation (86.3%) was significantly better than predicted (74.8%) on the basis of the risk factors present in each patient at the time of entry into the study. The findings suggest that hypopigmentation is a factor that beneficially influences the prognosis of MM, and that the mechanisms that inhibit or destroy normal melanocytes in patients with MM may also slow the growth of this cancer.
Similar articles
- Hypopigmentation, vitiligo, and melanoma. New data, more enigmas.
Nordlund JJ. Nordlund JJ. Arch Dermatol. 1987 Aug;123(8):1005-8. Arch Dermatol. 1987. PMID: 3631979 No abstract available. - [Cutaneous achromia and malignant melanoma].
Barrière H, Litoux P, Le Lay M, Bureau B, Stalder JF, Dreno B. Barrière H, et al. Ann Dermatol Venereol. 1984;111(11):991-6. Ann Dermatol Venereol. 1984. PMID: 6524818 French. - Giant melanin granules in vitiliginous achromia with malignant melanoma.
Ortonne JP, Perrot H. Ortonne JP, et al. Acta Derm Venereol. 1978;58(6):475-80. Acta Derm Venereol. 1978. PMID: 83067 - [Malignant melanoma, leukoderma and vitiligo].
Kraus L, Landthaler M. Kraus L, et al. Z Hautkr. 1980 Feb 15;55(4):218-31. Z Hautkr. 1980. PMID: 6996365 Review. German. - Immunological basis of melanoma-associated vitiligo-like depigmentation.
González R, Torres-López E. González R, et al. Actas Dermosifiliogr. 2014 Mar;105(2):122-7. doi: 10.1016/j.ad.2012.06.018. Epub 2012 Nov 10. Actas Dermosifiliogr. 2014. PMID: 23146137 Review. English, Spanish.
Cited by
- Mendelian Randomization Analysis reveals Inverse Genetic Risks between Skin Cancers and Vitiligo.
Rashid S, Molotkov I, Klebanov N, Shaughnessy M, Daly MJ, Artomov M, Tsao H. Rashid S, et al. JID Innov. 2023 Jul 8;3(6):100217. doi: 10.1016/j.xjidi.2023.100217. eCollection 2023 Nov. JID Innov. 2023. PMID: 38034848 Free PMC article. - Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
Bayless NL, Bluestone JA, Bucktrout S, Butterfield LH, Jaffee EM, Koch CA, Roep BO, Sharpe AH, Murphy WJ, Villani AC, Walunas TL. Bayless NL, et al. J Immunother Cancer. 2021 Sep;9(9):e002627. doi: 10.1136/jitc-2021-002627. J Immunother Cancer. 2021. PMID: 34479924 Free PMC article. Review. - Risk of skin cancer in patients with vitiligo in Denmark: A nationwide cohort study.
Jørgensen MG, Toyserkani NM, Egeberg A, Sørensen JA. Jørgensen MG, et al. JAAD Int. 2020 May 23;1(1):31-38. doi: 10.1016/j.jdin.2020.03.004. eCollection 2020 Jul. JAAD Int. 2020. PMID: 34409316 Free PMC article. - The Role of the NKG2D in Vitiligo.
Plaza-Rojas L, Guevara-Patiño JA. Plaza-Rojas L, et al. Front Immunol. 2021 Feb 26;12:624131. doi: 10.3389/fimmu.2021.624131. eCollection 2021. Front Immunol. 2021. PMID: 33717132 Free PMC article. Review. - Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.
Uhara H, Kiyohara Y, Uehara J, Fujisawa Y, Takenouchi T, Otsuka M, Uchi H, Fukushima S, Minami H, Hatsumichi M, Yamazaki N. Uhara H, et al. J Dermatol. 2021 May;48(5):592-599. doi: 10.1111/1346-8138.15804. Epub 2021 Mar 14. J Dermatol. 2021. PMID: 33715172 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical